Author

Paweł Buda

Observed names: Buda, Pawel, Buda, Paweł, PAWEL BUDA, Pawel Buda

Institution: Celon Pharma (Poland)

Observed institutions: Jagiellonian University, Lund University, Medical University of Warsaw, Celon Pharma (Poland), Postgraduate School of Molecular Medicine

ORCID: 0000-0002-1304-6871

Observed ORCID: 0000-0002-1304-6871

OpenAlex ID: A5059306283

The Complement Inhibitor CD59 Regulates Insulin Secretion by Modulating Exocytotic Events

2014 · Ulrika Krus, Ben C. King, et al. · Cell Metabolism · 86

Prevalence of genes encoding extracellular proteases inStaphylococcus aureus— important targets triggering immune responsein vivo

2012 · Michal Zdzalik, Abdulkarim Y. Karim, et al. · FEMS Immunology & Medical Microbiology · 41

Elevated Basal Insulin Secretion in Type 2 Diabetes Caused by Reduced Plasma Membrane Cholesterol

2016 · Vini Nagaraj, Abdulla S. Kazim, et al. · Molecular Endocrinology · 20

Eukaryotic Translation Initiation Factor 3 Subunit E Controls Intracellular Calcium Homeostasis by Regulation of Cav1.2 Surface Expression

2013 · Pawel Buda, Thomas Reinbothe, et al. · PLoS ONE · 20

Discovery and development of CPL207280 as new GPR40/FFA1 agonist

2021 · Mateusz Mach, Katarzyna Bazydło-Guzenda, et al. · European Journal of Medicinal Chemistry · 15

CPL207280, a Novel G Protein–Coupled Receptor 40/Free Fatty Acid Receptor 1–Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals

2021 · Katarzyna Bazydlo-Guzenda, Pawel Buda, et al. · Molecular Pharmacology · 13

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey

2021 · Katarzyna Bazydlo-Guzenda, Pawel Buda, et al. · PLoS ONE · 8

First‐in‐human study of CPL207280 , a novel G‐protein‐coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration

2024 · Katarzyna Bazydło‐Guzenda, Katarzyna Jarus‐Dziedzic, et al. · Diabetes Obesity and Metabolism · 5

Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes

2026 · Aleksandra A. Czyrek, Daniel Krowarsch, et al. · Molecular Biomedicine · 2

2333-PUB: CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes

2019 · KATARZYNA BAZYDLO-GUZENDA, PAWEL BUDA, et al. · Diabetes · 2

CCDC 2076005: Experimental Crystal Structure Determination

2021 · Mach, Mateusz, Bazydło-Guzenda, Katarzyna, et al. · The Cambridge Structural Database · 1

Discovery of CPL207-280CA, an Effective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes

2018 · KATARZYNA BAZYDLO, PAWEL BUDA, et al. · Diabetes · 1

Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes - raw data

2026 · Czyrek, Aleksandra, Krowarsch, Daniel, et al. · Uniwersytet Wrocławski

Targeting the voltage-gated calcium channels as treatment for type 2 diabetes

2015 · Paweł Buda · Lund University Publications (Lund University)

CD59 is required for pancreatic beta cell insulin exocytosis

2014 · Ulrika Krus, Benjamin King, et al. · Molecular Immunology

Activity-Dependent Cav1.2 Cluster Surface Expression in Insulin-Secreting Cells

2010 · Enming Zhang, Pawel Buda, et al. · Biophysical Journal

Works count: 16

Citation count: 214

H-index: 7

I10-index: 6